Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6697121 | 1.00 | KMT2A (0.33) | KMT2ACHRM2CHRM1CHRM3 | |
| SCHEMBL6700585 | 0.92 | KMT2A (0.32) | KMT2ACHRM2CHRM1CHRM3 | |
| SCHEMBL6693573 | 0.92 | KMT2A (0.32) | KMT2ACHRM2CHRM1CHRM3 | |
| SCHEMBL6695930 | 0.92 | KMT2A (0.32) | KMT2ACHRM2CHRM1CHRM3 | |
| SCHEMBL6696364 | 0.91 | CHRM2 (0.32) | KMT2ACHRM2CHRM1CHRM3 | |
| SCHEMBL6697689 | 0.91 | CHRM2 (0.32) | KMT2ACHRM2CHRM1CHRM3 | |
| SCHEMBL6698653 | 0.91 | CHRM2 (0.32) | KMT2ACHRM2CHRM1CHRM3 | |
| SCHEMBL6784303 | 0.90 | CHRM2 (0.31) | KMT2ACHRM2CHRM1CHRM3 | |
| SCHEMBL6694925 | 0.90 | CHRM2 (0.33) | KMT2ACHRM2CHRM1CHRM3 | |
| SCHEMBL6787065 | 0.90 | CHRM2 (0.31) | KMT2ACHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831096-B2 | Effective against both A and B forms of influenza; oral bioavailability | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| US-20040097471-A1 | Inhibitors of neuraminidases | ABBVIE INC. | 2004-05-20 | — | — | US | disclosed |
| US-6455571-B1 | ESPECIALLY, INFLUENZA NEURAMINIDASE. | ABBOTT LABORATORIES | 2002-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097471-A1 | Inhibitors of neuraminidases | NEU1, NEU2, NEU4 | KMT2A 3372/4885CHRM2 620/4885CHRM1 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.